TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients

被引:65
作者
Halvorsen, Ann R. [1 ]
Silwal-Pandit, Laxmi [1 ]
Meza-Zepeda, Leonardo A. [2 ,3 ]
Vodak, Daniel [2 ]
Phuong Vu [1 ]
Sagerup, Camilla [1 ]
Hovig, Eivind [2 ,4 ,5 ]
Myklebost, Ola [2 ]
Borresen-Dale, Anne-Lise [1 ,6 ]
Brustugun, Odd T. [1 ,7 ]
Helland, Aslaug [1 ,7 ]
机构
[1] Norwegian Radium Hosp, Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway
[2] Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, N-0450 Oslo, Norway
[3] Oslo Univ Hosp, Inst Canc Res, Dept Core Facil, Genom Core Facil, N-0450 Oslo, Norway
[4] Univ Oslo, Dept Informat, Oslo, Norway
[5] Oslo Univ Hosp, Inst Canc Genet & Informat, N-0450 Oslo, Norway
[6] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway
[7] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Oncol, Oslo, Norway
关键词
P53; MUTATIONS; SOMATIC MUTATIONS; SURVIVAL; GENE;
D O I
10.3389/fgene.2016.00085
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: TP53 mutations are among the most common mutations found in lung cancers, identified as an independent prognostic factor in many types of cancers. The purpose of this study was to investigate the frequency and prognostic impact of TP53 mutations in never-smokers and in different histological subtypes of lung cancer. Methods: We analyzed tumor tissue from 394 non-small cell carcinomas including adenocarcinomas (n = 229), squamous cell carcinomas (n = 112), large cell carcinomas (n = 30), and others (n = 23) for mutations in TP53 by the use of Sanger sequencing (n = 394) and next generation sequencing (n = 100). Results: TP53 mutations were identified in 47.2% of the samples, with the highest frequency (65%) of mutations among squamous cell carcinomas. Among never smokers, 36% carried a TP53 mutation, identified as a significant independent negative prognostic factor in this subgroup. For large cell carcinomas, a significantly prolonged progression free survival was found for those carrying a TP53 mutation. In addition, the frequency of frameshift mutations was doubled in squamous cell carcinomas (20.3%) compared to adenocarcinomas (9.1 %). Conclusion: TP53 mutation patterns differ between the histological subgroups of lung cancers, and are also influenced by smoking history. This indicates that the histological subtypes in lung cancer are genetically different, and that smoking-induced TP53 mutations may have a different biological impact than TP53 mutations occurring in never-smokers.
引用
收藏
页数:10
相关论文
共 31 条
[21]   Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer [J].
Molina-Vila, Miguel A. ;
Bertran-Alamillo, Jordi ;
Gasco, Amaya ;
Mayo-de-las-Casas, Clara ;
Sanchez-Ronco, Maria ;
Pujantell-Pastor, Laia ;
Bonanno, Laura ;
Favaretto, Adolfo G. ;
Cardona, Andres F. ;
Vergnenegre, Alain ;
Majem, Margarita ;
Massuti, Bartomeu ;
Moran, Teresa ;
Carcereny, Enric ;
Viteri, Santiago ;
Rosell, Rafael .
CLINICAL CANCER RESEARCH, 2014, 20 (17) :4647-4659
[22]   Mutant TP53 Posttranslational Modifications: Challenges and Opportunities [J].
Nguyen, Thuy-Ai ;
Menendez, Daniel ;
Resnick, Michael A. ;
Anderson, Carl W. .
HUMAN MUTATION, 2014, 35 (06) :738-755
[23]   The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer [J].
Olivier, M ;
Langerod, A ;
Carrieri, P ;
Bergh, J ;
Klaar, S ;
Eyfjord, J ;
Theillet, C ;
Rodriguez, C ;
Lidereau, R ;
Bièche, I ;
Varley, J ;
Bignon, Y ;
Uhrhammer, N ;
Winqvist, R ;
Jukkola-Vuorinen, A ;
Niederacher, D ;
Kato, S ;
Ishioka, C ;
Hainaut, P ;
Borresen-Dale, AL .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1157-1167
[24]   Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes [J].
Olivier, Magali ;
Taniere, Philippe .
CURRENT OPINION IN ONCOLOGY, 2011, 23 (01) :88-92
[25]   Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers [J].
Pfeifer, GP ;
Denissenko, MF ;
Olivier, M ;
Tretyakova, N ;
Hecht, SS ;
Hainaut, P .
ONCOGENE, 2002, 21 (48) :7435-7451
[26]   TP53 mutations and survival in squamous-cell carcinoma of the head and neck [J].
Poeta, M. Luana ;
Manola, Judith ;
Goldwasser, Meredith A. ;
Forastiere, Arlene ;
Benoit, Nicole ;
Califano, Joseph A. ;
Ridge, John A. ;
Goodwin, Jarrard ;
Kenady, Daniel ;
Saunders, John ;
Westra, William ;
Sidransky, David ;
Koch, Wayne M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (25) :2552-2561
[27]   Interplay between nuclear transport and ubiquitin/SUMO modifications in the regulation of cancer-related proteins [J].
Rodriguez, Jose A. .
SEMINARS IN CANCER BIOLOGY, 2014, 27 :11-19
[28]   Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort [J].
Scoccianti, Chiara ;
Vesin, Aurelien ;
Martel, Ghislaine ;
Olivier, Magali ;
Brambilla, Elisabeth ;
Timsit, Jean-Francois ;
Tavecchio, Luca ;
Brambilla, Christian ;
Field, John K. ;
Hainaut, Pierre .
EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (01) :177-184
[29]   Lung cancer in never smokers - a different disease [J].
Sun, Sophie ;
Schiller, Joan H. ;
Gazdar, Adi F. .
NATURE REVIEWS CANCER, 2007, 7 (10) :778-790
[30]   The TP53 gene, tobacco exposure, and lung cancer [J].
Toyooka, S ;
Tsuda, T ;
Gazdar, AF .
HUMAN MUTATION, 2003, 21 (03) :229-239